9 completed, 6 active not recruiting, 6 recruiting, 6 unknown. 38 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 38 | Completed 9, Active not recruiting 6, Recruiting 6, Unknown 6, Terminated 5, Not yet recruiting 3, Withdrawn 3 |
| Phase 1 | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
Follow Mucosal Melanoma: new trials by email Literature Review of Mucosal Melanoma trials Research Report on Mucosal Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma Opdualag, Nivolumab - Cutaneous Melanoma, Melanoma Stage IV | Phase 2 | Recruiting | University Health Network, Toronto | 54 | 2026-11-30 | 2026-10-13 |
| Sintilimab Combined With Chemotherapy for Adjuvant Treatment of Mucosal Melanoma After Surgery Sintilimab, Dacarbazine or Temozolomide, Cisplatin - Mucosal Melanoma, PD-L1 Positive | Phase 2 | Recruiting | The First Hospital of Jilin University | 220 | 2026-04-10 | 2026-09-03 |
| Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation) Ipilimumab 3mg/kg and nivolumab 1mg/kg, Ipilimumab 1mg/kg Nivolumab 480mg and relatlimab 160mg, Nivolumab 480mg and relatlimab 160mg - Cutaneous Melanoma, Mucosal Melanoma | Phase 2 | Recruiting | Melanoma Institute Australia | 494 | 2026-02-09 | 2026-02-19 |
| Iparomlimab and Tuvoraleimab Injection in Combination With Bevacizumab, Albumin-bound Paclitaxel, and Carboplatin as First- or Second-line Treatment for Patients With Advanced Acral and Mucosal Melanoma Iparomlimab and Tuvoraleimab injection+Bev+nab-PC - Acral Melanoma, Mucosal Melanoma | Phase 2 | Not yet recruiting | Fudan University | 48 | 2026-02-01 | 2026-01-16 |
| Neo-adjuvant Immunotherapy in Patients With Localized Melanoma Ipilimumab (YervoyTM, 50 mg/10 mL solution), Nivolumab (OpdivoTM, 40 mg/4mL solution) - Cutaneous Melanoma, Stage III, Mucosal Melanoma | Phase 2 | Recruiting | UNICANCER | 50 | 2026-01-12 | 2026-07-21 |
| Combination of Carilizumab, Apatinib, and Radiotherapy for Advanced Mucosal Melanoma Carilizumab and Apatinib - Mucosal Melanoma | Phase 2 | Not yet recruiting | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 30 | 2025-11-30 | 2025-11-19 |
| Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma Pembrolizumab, Lenvatinib - Mucosal Melanoma | Phase 2 | Withdrawn | Melanoma Institute Australia | 2024-03-01 | 2024-06-26 | |
| Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point Inhibitor Pembrolizumab, Vactosertib - Acral Melanoma, Mucosal Melanoma | Phase 2 | Terminated | Yonsei University | 14 | 2023-02-09 | 2025-04-02 |
| Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 Olaparib - Recurrent Metastatic Melanoma, Cutaneous Melanoma | Phase 2 | Withdrawn | Dana-Farber Cancer Institute | 2022-10-04 | 2024-01-19 | |
| Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery Biospecimen Collection, Bone Scan, Cabozantinib S-malate - Anal Melanoma, Bladder Melanoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 101 | 2022-08-11 | 2026-08-04 |
| A Study to Assess YH003 in Combination with Pebolizumab and Albumin Paclitaxel Injection in Subjects with Unresectable/metastatic Mucosal Melanoma YH003, Pembrolizumab, albumin paclitaxel - Mucosal Melanoma | Phase 2 | Completed | Eucure (Beijing) Biopharma Co., Ltd | 20 | 2022-06-13 | 2025-01-06 |
| Axitinib and Nivolumab for the Treatment of Mucosal Melanoma Nivolumab and/or Ipilimumab, Stereotactic Body Radiation Therapy (SBRT), axitinib - Mucosal Melanoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 20 | 2022-05-17 | 2026-02-18 |
| Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6 Nemvaleukin Alfa Subcutaneous, Nemvaleukin Alfa Intravenous, Nemvaleukin Alfa Intravenous Less Frequent Dosing - Cutaneous Melanoma, Mucosal Melanoma | Phase 2 | Terminated | Mural Oncology, Inc | 173 | 2021-09-27 | 2025-06-10 |
| A Beta-only IL-2 ImmunoTherapY Study MDNA11, Pembrolizumab (KEYTRUDA®) - Advanced Solid Tumor, Unresectable Solid Tumor | Phase 1 / Phase 2 | Recruiting | Medicenna Therapeutics, Inc. | 160 | 2021-08-27 | 2026-10-13 |
| Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma Lenvatinib, Pembrolizumab - Mucosal Melanoma, Neoadjuvant Treatment | Phase 2 | Not yet recruiting | Peking University Cancer Hospital & Institute | 26 | 2020-12-30 | 2020-11-13 |
| Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy Dietary Intervention, Quality-of-Life Assessment, Questionnaire Administration - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 50 | 2020-06-24 | 2026-01-30 |
| Maintenance Treatment of Toripalimab(JS001) in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma Toripalimab, chemotherapy in combination with Endostar - Mucosal Melanoma | Phase 2 | Unknown | Fudan University | 31 | 2020-06-20 | 2020-07-15 |
| Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Phase II Study Toripalimab, Temozolomide - Mucosal Melanoma | Phase 2 | Unknown | Peking University Cancer Hospital & Institute | 294 | 2020-05-30 | 2022-01-25 |
| Toripalimab in Combination With Axitinib in Patients With Localized Mucosal Melanoma TORIPALIMAB INJECTION(JS001 ) Axitinib tablet (Inlyta®) - Mucosal Melanoma | Phase 2 | Unknown | Peking University Cancer Hospital & Institute | 30 | 2019-08-06 | 2022-01-31 |
| Apatinib Plus SHR1210 in Advanced Mucosal Melanoma apatinib plus SHR-1210 - Mucosal Melanoma, Advanced Cancer | Phase 2 | Unknown | Henan Cancer Hospital | 40 | 2019-06-04 | 2019-06-14 |
Showing 20 of 38. Sign in to see all of them.
Melanoma (18) · Uveal Melanoma (8) · Neoplasms (3) · Esophageal Neoplasms (2) · Uterine Cervical Neoplasms (2) · Carcinoma, Basal Cell (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Fallopian Tube Neoplasms (1) · Mesothelioma, Malignant (1) · Neoplasm Metastasis (1) · Neurofibrosarcoma (1)
Neoplasms by Histologic Type (18) · Neoplasms by Site (18) · Neoplasms, Germ Cell and Embryonal (18) · Neoplasms, Nerve Tissue (18) · Neuroectodermal Tumors (18) · Neuroendocrine Tumors (18) · Nevi and Melanomas (18) · Skin Diseases (18) · Skin and Connective Tissue Diseases (18) · Skin Neoplasms (17) · Neoplasms (15) · Eye Diseases (8) · Eye Neoplasms (8) · Uveal Diseases (8) · Uveal Neoplasms (8)
Nivolumab (9) · pembrolizumab (9) · Ipilimumab (8) · CTLA-4 Antigen (4) · Axitinib (2) · Disulfides (2) · Immunoglobulin G (2) · Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · Temozolomide (2) · apatinib (2) · lenvatinib (2) · relatlimab (2) · toripalimab (2) · 130-nm albumin-bound paclitaxel (1)
National Cancer Institute (NCI) (7) · Peking University Cancer Hospital & Institute (3) · Dana-Farber Cancer Institute (2) · Fudan University (2) · M.D. Anderson Cancer Center (2) · Melanoma Institute Australia (2) · Academic and Community Cancer Research United (1) · AnewPharma (1) · Ascentage Pharma Group Inc. (1) · Craig L Slingluff, Jr (1) · Eucure (Beijing) Biopharma Co., Ltd (1) · Fred Hutchinson Cancer Center (1) · Georgetown University (1) · Henan Cancer Hospital (1) · Medicenna Therapeutics, Inc. (1)
United States (20) · China (11) · Australia (5) · Canada (4) · South Korea (3) · Spain (2) · France (1) · Ireland (1) · Italy (1) · Portugal (1) · Switzerland (1) · Taiwan (1) · United Kingdom (1)
Alexander N Shoushtari (1) · Alexander Shoushtari (1) · Alexander Shoushtari, MD (1) · Arash Yavari, MBBS (1) · Ari M Vanderwalde (1) · Christopher D Lao (1) · Craig L Slingluff, Jr., M.D. (1) · Craig Slingluff (1) · Erez Baruch, MD,PHD (1) · F. Stephen Hodi, MD (1) · Georgina Long (1) · Georgina Long, MBBS, PhD (1) · Jeffrey Weber (1) · Jing Ding, Master (1) · Jun Guo, M.D (1)
PMID 36648215, PMID 25609545, PMID 30588103, PMID 34413169, PMID 35121932, PMID 36856617, PMID 37104746, PMID 37592104, PMID 39342463, PMID 39633321, PMID 40638872, PMID 40811146, PMID 42093981
U01CA154967 (2), U10CA180821 (2), U10CA180888 (2), 2023 (1), 2025 (1), P30CA015083 (1), P30CA015704 (1), P30CA076292 (1), U10CA032102 (1)